Laura J Havrilesky

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4435270/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Catastrophic health expenditures, insurance churn, and nonemployment among gynecologic cancer patients in the United States. American Journal of Obstetrics and Gynecology, 2022, 226, 384.e1-384.e13.	1.3	8
2	Out-of-network bills among privately insured patients undergoing hysterectomy. American Journal of Obstetrics and Gynecology, 2022, 226, 543.e1-543.e45.	1.3	1
3	Reducing non-surgical readmissions on a gynecologic oncology service. Gynecologic Oncology, 2022,	1.4	1
4	Promoting timely goals of care conversations between gynecologic cancer patients at high-risk of death and their providers. Gynecologic Oncology, 2022, 164, 288-294.	1.4	11
5	Malnutrition as a risk factor for post-operative morbidity in gynecologic cancer: Analysis using a national surgical outcomes database. Gynecologic Oncology, 2022, 165, 309-316.	1.4	10
6	NRG-CC008: A nonrandomized prospective clinical trial comparing the non-inferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers [SOROCk] Journal of Clinical Oncology, 2022, 40, TPS10615-TPS10615.	1.6	2
7	Development of a predictive model for emergency room utilization and unanticipated hospital admission in patients receiving cancer treatment for solid tumor malignancies Journal of Clinical Oncology, 2022, 40, e18674-e18674.	1.6	0
8	Association of Medicaid expansion with mortality from gynecologic cancers. American Journal of Obstetrics and Gynecology, 2021, 224, 323-325.	1.3	6
9	Universal screening for Lynch syndrome in uterine cancer patients: A quality improvement initiative. Gynecologic Oncology, 2021, 160, 169-174.	1.4	7
10	Results and Clinical Utilization of Foundation Medicine Molecular Tumor Profiling in Uterine and Ovarian Cancers. Targeted Oncology, 2021, 16, 109-118.	3.6	3
11	Evaluation of pelvic washing specimens in patients with endometrial cancer: Cytomorphological features, diagnostic agreement, and pathologist experience. Cancer Cytopathology, 2021, 129, 517-525.	2.4	5
12	92741 Racial differences in patient-reported distress among women with endometrial cancer. Journal of Clinical and Translational Science, 2021, 5, 86-87.	0.6	0
13	Patient Preferences for Outcomes Following DCIS Management Strategies: A Discrete Choice Experiment. JCO Oncology Practice, 2021, 17, e1639-e1648.	2.9	4
14	Chemotherapy discontinuation processes in a gynecologic oncology population. Gynecologic Oncology, 2021, 161, 508-511.	1.4	5
15	Risk and distribution of venous thromboembolic events during treatment for advanced endometrial cancer Journal of Clinical Oncology, 2021, 39, e17565-e17565.	1.6	0
16	Surveillance for gestational trophoblastic neoplasia following molar pregnancy: a cost-effectiveness analysis. American Journal of Obstetrics and Gynecology, 2021, 225, 513.e1-513.e19.	1.3	5
17	Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer. Gynecologic Oncology, 2021, 163, 50-56.	1.4	1
18	A quality improvement initiative to reduce venous thromboembolism on a gynecologic oncology service. Gynecologic Oncology, 2021, 162, 120-127.	1.4	2

#	Article	IF	CITATIONS
19	The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens. Gynecologic Oncology, 2021, 162, 440-446.	1.4	2
20	Medicaid Expansion Reduced Uninsured Surgical Hospitalizations And Associated Catastrophic Financial Burden. Health Affairs, 2021, 40, 1294-1303.	5.2	0
21	Cost-Effectiveness of Venous Thromboembolism Prophylaxis During Neoadjuvant Chemotherapy for Ovarian Cancer. JCO Oncology Practice, 2021, 17, e1075-e1084.	2.9	10
22	Evaluation of the clinical Index of Stable febrile neutropenia risk stratification system for management of febrile neutropenia in gynecologic oncology patients. Gynecologic Oncology Reports, 2021, 37, 100853.	0.6	0
23	Primary cytoreductive surgery for advanced stage endometrial cancer: a systematic review and meta-analysis. American Journal of Obstetrics and Gynecology, 2021, 225, 237.e1-237.e24.	1.3	22
24	Associations of Insurance Churn and Catastrophic Health Expenditures With Implementation of the Affordable Care Act Among Nonelderly Patients With Cancer in the United States. JAMA Network Open, 2021, 4, e2124280.	5.9	8
25	Adjuvant treatment and outcomes for patients with stage IIIA grade 1 endometrioid endometrial cancer. International Journal of Gynecological Cancer, 2021, 31, ijgc-2021-002884.	2.5	2
26	Opportunities to Advance the Delivery of High-Quality, Goal-Concordant End-of-Life Care in Ovarian Cancer. JCO Oncology Practice, 2021, , OP2100699.	2.9	0
27	Cost-effectiveness of bacteriuria screening before urogynecologic surgery. American Journal of Obstetrics and Gynecology, 2021, , .	1.3	Ο
28	The cost-effectiveness of ertapenem for the treatment of chorioamnionitis after cesarean delivery. Journal of Maternal-Fetal and Neonatal Medicine, 2020, 33, 4096-4101.	1.5	3
29	Cellâ€free DNA for Down syndrome screening in obese women: Is it a costâ€effective strategy?. Prenatal Diagnosis, 2020, 40, 173-178.	2.3	4
30	Off-study utilization of experimental therapies: Analysis of GOG249-eligible cohorts using real world data. Gynecologic Oncology, 2020, 156, 154-161.	1.4	8
31	Cost-effectiveness analysis comparing "PARP inhibitors-for-all―to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer. Gynecologic Oncology, 2020, 159, 483-490.	1.4	19
32	Are Videos or Text Better for Describing Attributes in Stated-Preference Surveys?. Patient, 2020, 13, 401-408.	2.7	15
33	Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion. International Journal of Gynecological Cancer, 2020, 30, 1738-1747.	2.5	8
34	Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy?. Gynecologic Oncology, 2020, 156, 568-574.	1.4	15
35	Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment. Gynecologic Oncology, 2020, 156, 561-567.	1.4	21
36	Incidence of venous thromboembolism among patients receiving neoadjuvant chemotherapy for advanced epithelial ovarian cancer. International Journal of Gynecological Cancer, 2020, 30, 491-497.	2.5	20

#	Article	IF	CITATIONS
37	Genetic counseling referrals after next generation sequencing testing Journal of Clinical Oncology, 2020, 38, 1515-1515.	1.6	0
38	Venous thromboembolism prophylaxis in ambulatory cancer patients initiating chemotherapy: A cost-effectiveness analysis Journal of Clinical Oncology, 2020, 38, 7074-7074.	1.6	2
39	An analysis of trends in prostate cancer treatment from a CMS database Journal of Clinical Oncology, 2020, 38, e19288-e19288.	1.6	0
40	Induction of Labor versus Scheduled Cesarean in Morbidly Obese Women: A Cost-Effectiveness Analysis. American Journal of Perinatology, 2019, 36, 399-405.	1.4	5
41	Gender variation in Medicare utilization and payments in gynecologic oncology. Gynecologic Oncology, 2019, 154, 602-607.	1.4	4
42	Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer. Cancer, 2019, 125, 4399-4406.	4.1	16
43	Reduction in opioid use and postoperative pain scores after elective laparotomy with implementation of enhanced recovery after surgery protocol on a gynecologic oncology service. International Journal of Gynecological Cancer, 2019, 29, 935-943.	2.5	25
44	Associations between lymphovascular space invasion, nodal recurrence, and survival in patients with surgical stage I endometrioid endometrial adenocarcinoma. World Journal of Surgical Oncology, 2019, 17, 80.	1.9	25
45	A pilot study of lower extremity lymphedema, lower extremity function, and quality of life in women after minimally invasive endometrial cancer staging surgery. Gynecologic Oncology, 2019, 153, 399-404.	1.4	13
46	Preferences of women with epithelial ovarian cancer for aspects of genetic testing. Gynecologic Oncology Research and Practice, 2019, 6, 1.	3.6	13
47	Impact of a documentation intervention on health-assessment metrics on an inpatient gynecologic oncology service. Gynecologic Oncology, 2019, 153, 385-390.	1.4	2
48	Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer. Gynecologic Oncology, 2019, 152, 445-451.	1.4	3
49	Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies. Gynecologic Oncology, 2019, 154, 199-206.	1.4	23
50	Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer. Gynecologic Oncology, 2019, 153, 555-561.	1.4	19
51	Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy. Gynecologic Oncology, 2019, 153, 376-380.	1.4	17
52	Radiation Records in the National Cancer Database: Variations in Coding and/or Practice Can Significantly Alter Survival Results. JCO Clinical Cancer Informatics, 2019, 3, 1-9.	2.1	20
53	Simulated Costs of the ASCO Patient-Centered Oncology Payment Model in Medicare Beneficiaries With Newly Diagnosed Advanced Ovarian Cancer. Journal of Oncology Practice, 2019, 15, e1018-e1027.	2.5	2
54	U.S. Food and Drug Administration–Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer. Obstetrics and Gynecology, 2019, 133, 795-802.	2.4	28

#	Article	IF	CITATIONS
55	Changes in insurance coverage for cancer patients receiving brachytherapy before and after enactment of the Affordable Care Act. Brachytherapy, 2019, 18, 115-121.	0.5	5
56	The use of patient-reported outcome tools in Gynecologic Oncology research, clinical practice, and value-based care. Gynecologic Oncology, 2018, 148, 12-18.	1.4	22
57	Is it reasonable to administer pegfilgrastim on day 1 of a myelosuppressive chemotherapy regimen? A cost-utility analysis. Cancer Treatment and Research Communications, 2018, 14, 21-25.	1.7	3
58	Health Care Disparities in Cancer Patients Receiving Radiation: Changes in Insurance Status After Medicaid Expansion Under the Affordable Care Act. International Journal of Radiation Oncology Biology Physics, 2018, 101, 9-20.	0.8	15
59	Society of Gynecologic Oncology Future of Physician Payment Reform Task Force report: The Endometrial Cancer Alternative Payment Model (ECAP). Gynecologic Oncology, 2018, 149, 232-240.	1.4	8
60	Estimating the number of potential family members eligible for <i>BRCA1</i> and <i>BRCA2</i> mutation testing in a "Traceback―approach. Genetic Epidemiology, 2018, 42, 117-122.	1.3	6
61	Estimating Cost-effectiveness of a Multimodal Ovarian Cancer Screening Program in the United States. JAMA Oncology, 2018, 4, 190.	7.1	30
62	Trends in Insurance Status Among Patients Diagnosed With Cancer Before and After Implementation of the Affordable Care Act. Journal of Oncology Practice, 2018, 14, e92-e102.	2.5	34
63	Hysterectomy with sentinel lymph node biopsy in the setting of pre-operative diagnosis of endometrial intraepithelial neoplasia: A cost-effectiveness analysis. Gynecologic Oncology, 2018, 151, 506-512.	1.4	10
64	Gender trends in gynecologic oncology authorship: Implications for the critical evaluation of gender distribution in academic rank and leadership positions. Gynecologic Oncology, 2018, 151, 542-546.	1.4	19
65	High-volume providers and brachytherapy practice: A Medicare provider utilization and payment analysis. Brachytherapy, 2018, 17, 906-911.	0.5	3
66	Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?. Gynecologic Oncology, 2017, 144, 125-129.	1.4	9
67	Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma. Gynecologic Oncology, 2017, 144, 531-535.	1.4	10
68	Increasing utilization of intensity modulated radiation therapy in vulvar cancer: National Practice Patterns 2004–2012. Journal of Radiation Oncology, 2017, 6, 197-206.	0.7	0
69	Cost-effectiveness of opportunistic salpingectomy for ovarian cancer prevention. Gynecologic Oncology, 2017, 146, 373-379.	1.4	45
70	Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers. Gynecologic Oncology, 2017, 145, 549-554.	1.4	22
71	The "value―of value in gynecologic oncology practice in the United States: Society of Gynecologic Oncology evidence-based review and recommendations. Gynecologic Oncology, 2017, 145, 185-191.	1.4	4
72	Use of a novel sentinel lymph node mapping algorithm reduces the need for pelvic lymphadenectomy in low-grade endometrial cancer. Gynecologic Oncology, 2017, 147, 535-540.	1.4	29

#	Article	IF	CITATIONS
73	The costs of adding laparoscopy to the management of advanced stage epithelial ovarian cancer. Gynecologic Oncology, 2017, 146, 441-442.	1.4	0
74	Insurance coverage among women diagnosed with a gynecologic malignancy before and after implementation of the Affordable Care Act. Gynecologic Oncology, 2017, 146, 457-464.	1.4	29
75	Raceâ€specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patients. Cancer, 2017, 123, 4004-4012.	4.1	25
76	Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer. Annals of Surgical Oncology, 2017, 24, 3116-3123.	1.5	17
77	Disparities in the surgical staging of high-grade endometrial cancer in the United States. Gynecologic Oncology Research and Practice, 2017, 4, 1.	3.6	17
78	Cost Comparison of Genetic Testing Strategies in Women With Epithelial Ovarian Cancer. Journal of Oncology Practice, 2017, 13, e120-e129.	2.5	11
79	Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?. Journal of Clinical Oncology, 2017, 35, 3999-4002.	1.6	14
80	ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian Cancer. Journal of Oncology Practice, 2017, 13, e1030-e1039.	2.5	10
81	Is There a Role for Ovarian Cancer Screening in High-Risk Women?. Journal of Clinical Oncology, 2017, 35, 1384-1386.	1.6	8
82	Tumor grade and chemotherapy response in endometrioid endometrial cancer. Gynecologic Oncology Reports, 2016, 17, 3-6.	0.6	15
83	Analysis of in vitro chemoresponse assays in endometrioid endometrial adenocarcinoma: an observational ancillary analysis. Gynecologic Oncology Research and Practice, 2016, 3, 13.	3.6	1
84	Performance of sentinel lymph node biopsy in high-risk endometrial cancer. Gynecologic Oncology Reports, 2016, 17, 69-71.	0.6	44
85	Impact of postoperative nausea and vomiting prophylaxis with dexamethasone on the risk of recurrence of endometrial cancer. Current Medical Research and Opinion, 2016, 32, 453-458.	1.9	14
86	Sensitivity of ovarian cancer cells to acetaminophen reveals biological pathways that affect patient survival. Molecular and Clinical Oncology, 2016, 4, 399-404.	1.0	7
87	Body mass index and mortality in endometrial cancer: A systematic review and meta-analysis. Gynecologic Oncology, 2016, 140, 184-190.	1.4	120
88	Lumbee Native American ancestry and the incidence of aggressive histologic subtypes of endometrial cancer. Gynecologic Oncology Reports, 2015, 13, 49-52.	0.6	3
89	Patient-reported outcomes as end points and outcome indicators in solid tumours. Nature Reviews Clinical Oncology, 2015, 12, 358-370.	27.6	55
90	Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG oncology/gynecologic oncology group study. Gynecologic Oncology, 2015, 139, 541-545.	1.4	47

#	Article	IF	CITATIONS
91	Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: Is it cost-effective?. Gynecologic Oncology, 2015, 136, 43-47.	1.4	24
92	Vaginal Cuff Thermal Injury by Mode of Colpotomy at Total Laparoscopic Hysterectomy: A Randomized Clinical Trial. Journal of Minimally Invasive Gynecology, 2015, 22, 227-233.	0.6	9
93	A review of relative dose intensity and survival in patients with metastatic solid tumors. Critical Reviews in Oncology/Hematology, 2015, 93, 203-210.	4.4	100
94	A cost–utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: Incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer. Gynecologic Oncology, 2015, 136, 293-299.	1.4	24
95	Lymphatic mapping and sentinel lymph node dissection compared to complete lymphadenectomy in the management of early-stage vulvar cancer: A cost-utility analysis. Gynecologic Oncology, 2015, 136, 300-304.	1.4	34
96	Bariatric surgery as a means to decrease mortality in women with type I endometrial cancer — An intriguing option in a population at risk for dying of complications of metabolic syndrome. Gynecologic Oncology, 2015, 138, 597-602.	1.4	14
97	Patient and physician factors associated with participation in cervical and uterine cancer trials: An NRG/GOG247 study. Gynecologic Oncology, 2015, 138, 101-108.	1.4	13
98	Postoperative Pain Scores and Narcotic Use in Robotic-assisted Versus Laparoscopic Hysterectomy for Endometrial Cancer Staging. Journal of Minimally Invasive Gynecology, 2015, 22, 1004-1010.	0.6	14
99	Costs, Effectiveness, and Workload Impact of Management Strategies for Women With an Adnexal Mass. Journal of the National Cancer Institute, 2015, 107, 322.	6.3	16
100	Benefits and Harms of Breast Cancer Screening. JAMA - Journal of the American Medical Association, 2015, 314, 1615.	7.4	473
101	A multi-institutional study of outcomes in stage l–III uterine carcinosarcoma. Gynecologic Oncology, 2015, 139, 275-282.	1.4	25
102	Improving NCCN guideline-adherent care for ovarian cancer: Value of an intervention. Gynecologic Oncology, 2015, 138, 694-699.	1.4	13
103	Can We Maximize Both Value and Quality in Gynecologic Cancer Care? A Work in Progress. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e268-e275.	3.8	2
104	Patient preferences in advanced or recurrent ovarian cancer. Cancer, 2014, 120, 3651-3659.	4.1	68
105	Metformin is associated with improved survival in endometrial cancer. Gynecologic Oncology, 2014, 132, 438-442.	1.4	148
106	Cost of care using prophylactic negative pressure wound vacuum on closed laparotomy incisions. Gynecologic Oncology, 2014, 132, 684-689.	1.4	38
107	Palliative services enhance the quality and value of gynecologic cancer care. Gynecologic Oncology, 2014, 132, 1-2.	1.4	5
108	The complex triad of obesity, diabetes and race in Type I and II endometrial cancers: Prevalence and prognostic significance. Gynecologic Oncology, 2014, 133, 28-32.	1.4	54

#	Article	IF	CITATIONS
109	Relationship between minimally invasive hysterectomy, pelvic cytology, and lymph vascular space invasion: A single institution study of 458 patients. Gynecologic Oncology, 2014, 133, 211-215.	1.4	25
110	Quality of life in ICON7: need for patients' perspectives. Lancet Oncology, The, 2013, 14, 183-185.	10.7	18
111	A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer. Gynecologic Oncology, 2013, 128, 65-70.	1.4	89
112	Timing of end-of-life care discussion with performance on end-of-life quality indicators in ovarian cancer. Gynecologic Oncology, 2013, 130, 156-161.	1.4	94
113	Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer. Gynecologic Oncology, 2013, 130, 426-430.	1.4	57
114	How much is another randomized trial of lymph node dissection in endometrial cancer worth? A value of information analysis. Gynecologic Oncology, 2013, 131, 140-146.	1.4	16
115	In Reply. Obstetrics and Gynecology, 2013, 122, 1114.	2.4	0
116	Oral Contraceptive Pills as Primary Prevention for Ovarian Cancer. Obstetrics and Gynecology, 2013, 122, 139-147.	2.4	202
117	Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer. Gynecologic Oncology, 2012, 125, 631-634.	1.4	25
118	Costâ€effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinumâ€sensitive, recurrent ovarian cancer. Cancer, 2012, 118, 386-391.	4.1	14
119	Development of an ovarian cancer screening decision model that incorporates disease heterogeneity. Cancer, 2011, 117, 545-553.	4.1	30
120	Impact of a chemoresponse assay on treatment costs for recurrent ovarian cancer. American Journal of Obstetrics and Gynecology, 2010, 203, 160.e1-160.e7.	1.3	14
121	Cost Comparison Among Robotic, Laparoscopic, and Open Hysterectomy for Endometrial Cancer. Obstetrics and Gynecology, 2010, 116, 685-693.	2.4	162
122	Cost effectiveness of a test to detect metastases for endometrial cancer. Gynecologic Oncology, 2009, 112, 526-530.	1.4	6
123	Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment. Gynecologic Oncology, 2009, 113, 216-220.	1.4	101
124	Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer. Gynecologic Oncology, 2009, 114, 279-283.	1.4	24
125	Cost-effectiveness analysis of annual screening strategies for endometrial cancer. American Journal of Obstetrics and Gynecology, 2009, 200, 640.e1-640.e8.	1.3	28
126	Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecologic Oncology, 2008, 110, 374-382.	1.4	201

#	Article	IF	CITATIONS
127	Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it?. Gynecologic Oncology, 2008, 111, 179-187.	1.4	38
128	Cost Effectiveness of Intraperitoneal Compared With Intravenous Chemotherapy for Women With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study. Journal of Clinical Oncology, 2008, 26, 4144-4150.	1.6	42
129	The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer. Gynecologic Oncology, 2007, 104, 401-405.	1.4	75
130	Outcomes in surgical stage I uterine papillary serous carcinoma. Gynecologic Oncology, 2007, 105, 677-682.	1.4	99
131	Management of platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis. Gynecologic Oncology, 2007, 107, 211-218.	1.4	22
132	FDC-PET for management of cervical and ovarian cancer. Gynecologic Oncology, 2005, 97, 183-191.	1.4	245
133	Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. Gynecologic Oncology, 2005, 99, 689-695.	1.4	99
134	Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer. Gynecologic Oncology, 2004, 93, 429-434.	1.4	57
135	Weekly Low-Dose Carboplatin and Paclitaxel in the Treatment of Recurrent Ovarian and Peritoneal Cancer. Gynecologic Oncology, 2003, 88, 51-57.	1.4	72
136	The role of PET scanning in the detection of recurrent cervical cancer. Gynecologic Oncology, 2003, 90, 186-190.	1.4	118
137	Predictors of clinical outcomes in the laparoscopic management of adnexal masses. Obstetrics and Gynecology, 2003, 102, 243-251.	2.4	55
138	Prognostic Significance of p53 Mutation and p53 Overexpression in Advanced Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study. Journal of Clinical Oncology, 2003, 21, 3814-3825.	1.6	143
139	OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma. Cancer, 2001, 92, 2837-2844.	4.1	94